XORTX Therapeutics Inc. Common Shares (XRTX)
XRTX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | XRTX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Canada |
| IPO year | Not reported by the screener |
| SEC CIK | 0001729214 |
Financials
Foreign filer: no machine-readable annual figure in SEC data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These circumstances and conditions indicate the existence of a material uncertainty that raises substantial doubt about its ability to continue as a going concern." | 20-F 2026-03-20 |
| Cash and burn | $865K cash; operating cash flow -$692K a quarter. | Report 2025-12-31 |
| Shares outstanding | 1,392,444 (2025-12-31); 3,788,246 a year earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures. | Cover page 2025-12-31 |
| Reverse splits, 3 years | 1; latest 1-for-5 on 2026-04-06 | Source 2026-04-06 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Davidson & Company LLP, Vancouver, Canada | PCAOB Form AP 2026-03-24 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | Not filed | -$2.7M | -$2.8M | $865K | No debt tags | Needs four quarters | 20-F 2026-03-20 |
| FY 2021 2021-12-31 | Not filed | -$1.7M | -$6.1M | $18.9M | No debt tags | Needs four quarters | 20-F 2022-05-03 |
| FY 2020 2020-12-31 | Not filed | -$1.3M | -$728K | $171K | No debt tags | Needs four quarters | 20-F 2022-05-03 |
| FY 2019 2019-12-31 | Not filed | -$630K | -$250K | $59K | No debt tags | Needs four quarters | 20-F 2022-05-03 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
The SEC filing list did not load in time for this page. It is on SEC EDGAR and in the full dossier.
Price moves
| Window | Return |
|---|---|
| 1 week | +20.9% |
| 1 month | -34.5% |
| 3 months | -49.8% |
| Year to date | -60.9% |
| 1 year | -60.6% |
| From 52-week high | -66.1% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ONCO | Onconetix Inc. | $2.91 | -9.35% | $1.9M |
| PPCB | Propanc Biopharma Inc. | $1.89 | -2.62% | $2.0M |
| HCWB | HCW Biologics Inc. | $0.8000 | +3.48% | $1.8M |
| SXTP | 60 Degrees Pharmaceuticals Inc. | $0.4938 | -4.65% | $1.7M |
| ENLV | Enlivex Ltd. | $1.12 | -5.88% | $1.7M |
| CMND | Clearmind Medicine Inc. Common Shares | $4.18 | -7.67% | $2.1M |
| SBFM | Sunshine Biopharma Inc. | $2.60 | -3.70% | $2.1M |
| DCOY | Decoy Therapeutics Inc. | $0.9010 | -7.61% | $2.1M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier